Search Results - "Borzenkova, E."

Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults by Moiseev, I. S., Morozova, E. V., Bykova, T. A., Paina, O. V., Smirnova, A. G., Dotsenko, A. A., Borzenkova, E. S., Galimov, A. N., Gudognikova, Ya. V., Ekushov, K. A., Kozhokar, P. V., Osipova, A. A., Pirogova, O. V., Rudakova, T. A., Klimova, O. U., Tcvetkov, N. Yu, Kulagin, E. A., Surkova, E. A., Lapin, S. V., Rodionov, G. G., Moiseev, S. I., Serov, Yu. A., Zubarovskaya, L. S., Afanasyev, B. V.

“…Acute and chronic steroid-refractory graft-versus-host disease (srGVHD) is a life-threatening complication of allogeneic stem cell transplantation. There are a…”
Get full text

TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE by Lepik, E., Kozlov, A., Borzenkova, E., Zalyalov, Y., Lepik, K., Kondakova, E., Baykov, V., Moiseev, I., Mikhaylova, N., Afanasyev, B.

Get full text

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA by Fedorova, L., Lepik, K., Mikhailova, N., Kondakova, E., Komarova, Y., Popova, M., Kotselyabina, P., Borzenkova, E., Baykov, V., Moiseev, I., Kulagin, A.

Get full text

RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS by Lepik, K., Mikhaylova, N., Kondakova, E., Tsvetkova, L., Zalyalov, Y., Borzenkova, E., Moiseev, I., Baykov, V., Nikitina, T., Porfir'eva, N., Ionova, T., Afanasyev, B.

Get full text

RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS by Fedorova, L., Lepik, K., Mikhailova, N., Kondakova, E., Zalyalov, Y., Baykov, V., Babenko, E., Borzenkova, E., Tsvetkova, L., Stelmakh, L., Afanasyev, B.

Get full text

Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2nd line treatment before autologous hematopoietic stem cell transplantation (preliminary results) by Mamedova, A. A., Mochkin, N. E., Sarzhevskiy, V. O., Demina, E. A., Bogatyrev, V. S., Spornik, A. A., Samoylova, A. A., Rukavitsin, A. A., Smirnova, E. G., Bannikova, A. E., Melnichenko, V. Ya, Mikhaylova, N. B., Borzenkova, E. S., Stelmakh, L. V., Zalyalov, Yu. R., Semenova, A. A., Tumyan, G. S., Danilova, M. A., Konova, O. A., Falaleeva, N. A., Terekhova, A. Yu, Vernyuk, M. A., Chervontseva, A. M., Khayrullina, L. S., Maslov, A. A., Lysenko, I. B., Alekseeva, Yu. A., Pavlyuchenko, E. S., Mirsaitov, A. A., Zverkova, A. A., Ishmatova, I. V., Volchenkov, S. A., Motalkina, M. S., Zyuzgin, I. S.

“…Aim . To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical…”
Get full text

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience by Lepik, K. V., Mikhailova, N. V., Kondakova, E. V., Tsvetkova, L. A., Zalyalov, Yu. R., Borzenkova, E. S., Moiseev, I. S., Baykov, V. V., Afanasyev, B. A.

“…Background .  Using modern first-line chemotherapy more than 80 % of patients with classical Hodgkin’s lymphoma can be cured, however, in 15–20 % of cases…”
Get full text

49P Discontinuation of immune checkpoint inhibitors in patients with relapsed and refractory classical Hodgkin lymphoma by Fedorova, L., Lepik, K., Kotselyabina, P., Kondakova, E., Popova, M., Borzenkova, E., Moiseev, I., Mikhailova, N., Kulagin, A.

Get full text

903P Combination of nivolumab with brentuximab vedotin in therapy of relapsed and refractory Hodgkin lymphoma by Fedorova, L., Lepik, K., Mikhailova, N., Kondakova, E., Kotselyabina, P., Shmidt, D.I., Kozlov, A., Zalyalov, Y., Borzenkova, E., Baykov, V., Moiseev, I., Kulagin, A.

Get full text

834P Role of assessment of IL-6, IL-15 and soluble PD-L1 levels as prognostic and predictive biomarkers in nivolumab-treated relapsed/refractory Hodgkin lymphoma by Chekalov, A., Shmidt, D., Lepik, K., Yolshin, N., Volkov, N., Muslimov, A., Mikhailova, N., Kondakova, E., Tsvetkova, L., Zalyalov, Y., Borzenkova, E., Moiseev, I., Baykov, V., Ionova, T., Kulagin, A.

Get full text

1089PInvasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation by Popova, M, Rogacheva, Y, Volkova, A, Markova, I, Nikolaev, I, Ignatieva, S, Bogomolova, T, Kozlov, A, Lepik, K, Stelmakh, L, Beynarovich, A, Borzenkova, E, Darskaya, E, Kondakova, E, Mikhailova, N, Bondarenko, S, Moiseev, I, Zubarovskaya, L, Klimko, N, Afanasyev, B

“…Abstract Background This study focuses on epidemiology of IFD before and after allo-HSCT in children and adults with Hodgkin’s lymphoma (HL). Methods Single…”
Get full text

Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation by Popova, M., Rogacheva, Y., Volkova, A., Markova, I., Nikolaev, I., Ignatieva, S., Bogomolova, T., Kozlov, A., Lepik, K., Stelmakh, L., Beynarovich, A., Borzenkova, E., Darskaya, E., Kondakova, E., Mikhailova, N., Bondarenko, S., Moiseev, I., Zubarovskaya, L., Klimko, N., Afanasyev, B.

Get full text

1089P - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation by Popova, M., Rogacheva, Y., Volkova, A., Markova, I., Nikolaev, I., Ignatieva, S., Bogomolova, T., Kozlov, A., Lepik, K., Stelmakh, L., Beynarovich, A., Borzenkova, E., Darskaya, E., Kondakova, E., Mikhailova, N., Bondarenko, S., Moiseev, I., Zubarovskaya, L., Klimko, N., Afanasyev, B.

“…This study focuses on epidemiology of IFD before and after allo-HSCT in children and adults with Hodgkin’s lymphoma (HL). Single center prospective…”
Get full text

RESPONSE TO NIVOLUMAB AS ≥3 rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS by Lepik, K., Mikhaylova, N., Kondakova, E., Tsvetkova, L., Zalyalov, Y., Borzenkova, E., Moiseev, I., Baykov, V., Nikitina, T., Porfir'eva, N., Ionova, T., Afanasyev, B.

Get full text

PB1806 TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE by Lepik, E., Borzenkova, E., Kozlov, A., Zalyalov, Y., Lepik, K., Kondakova, E., Baykov, V., Moiseev, I., Mikhailova, N., Afanasyev, B.

“…Background: T‐cell lymphomas represent rare and heterogeneous group of aggressive non Hodgkin lymphomas. There are currently no standards for the treatment of…”
Get full text

COMBINATION OF NIVOLUMAB AND BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA by Mikhailova, N.B., Lepik, K.V., Kondakova, E.V., Kotselyabina, P.V., Kozlov, A.V., Zalyalov, Y.R., Popova, M.O., Borzenkova, E.S., Moiseev, I.S., Baykov, V.V., Afanasyev, B.V.

Get full text

PS1242 RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS by Fedorova, L., Lepik, K., Mikhailova, N., Kondakova, E., Zalyalov, Y., Baykov, V., Babenko, E., Borzenkova, E., Tsvetkova, L., Stelmakh, L., Afanasyev, B.

“…Background: Immune checkpoint inhibitors (ICI) may allow to achieve a durable remission in patients with resistant or refractory (r/r) classical Hodgkin…”
Get full text

PS1239 NIVOLUMAB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL): CLINICAL AND PATIENT‐REPORTED OUTCOMES by Lepik, K., Mikhailova, N., Kondakova, E., Tsvetkova, L., Zalyalov, Y., Borzenkova, E., Moiseev, I., Baykov, V., Nikitina, T., Porfir’eva, N., Ionova, T., Afanasyev, B.

“…Background: Treatment of pts with relapsed/refractory cHL is focused on achievement of survival benefits and improvement of patients’ quality of life (QoL)…”
Get full text

PS1285 INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS WITH HODGKIN'S LYMPHOMA by Popova, M., Rogacheva, Y., Volkova, A., Markova, I., Frolova, A., Shvetcov, A., Nikolaev, I., Goloshchapov, O., Ignatieva, S., Bogomolova, T., Kozlov, A., Lepik, K., Yuriy, Z., Stelmakh, L., Kondakova, E., Gevorgian, A., Beynarovich, A., Borzenkova, E., Darskaya, E., Vladovskaya, M., Bondarenko, S., Moiseev, I., Baykov, V., Mikhailova, N., Zubarovskaya, L., Klimko, N., Afanasyev, B.

“…Background: Data on invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplantation (allo‐HSCT) recipients with relapsed/refractory…”
Get full text

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA by Fedorova, L., Lepik, K., Mikhailova, N., Kondakova, E., Komarova, Y., Popova, M., Kotselyabina, P., Borzenkova, E., Baykov, V., Moiseev, I., Kulagin, A.

Get full text